Compare Organon & Co. Common Stock (OGN) vs WisdomTree Inc. Common Stock (WT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs WisdomTree Inc. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while WisdomTree Inc. Common Stock trades at $21.02 (market cap $3.27B). The key difference: Organon & Co. Common Stock and WisdomTree Inc. Common Stock are close in size by market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and WisdomTree Inc. Common Stock for 6 Days on average.
| OGN | WT | |
|---|---|---|
Market Cap | $3.62B | $3.27B |
Volume | 2,892,999 | 2,488,313 |
Sector | Health | Financials |
52-Week High | $13.81 | $25.04 |
52-Week Low | $5.70 | $10.73 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $4.02B |
Dividend Yield | 0.58% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
WisdomTree (WT) trades at $21.61, down 2.83% on the day, near the analyst low target of $21.30. The stock shows bearish technical signals with mixed oscillators, while fundamentals reveal strong profitability margins and consistent earnings beats. Recent news highlights WisdomTree's expansion into tokenized funds and new ETF launches, signaling growth initiatives.
The outlook is cautiously optimistic given analyst consensus favoring Buy ratings and a $26.05 price target, but risks include high valuation multiples and negative investing cash flow trends. Earnings momentum from recent beats supports upside potential, though investors face volatility from market sentiment and execution risks in new business lines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About WisdomTree Inc. Common Stock
WisdomTree provides exchange-traded products, model portfolios, and digital-asset-related products and services. Its digital offerings include tokenized funds, an institutional platform, and a blockchain-native wallet.
Read more on WT →
